Cathie Wood's ARK Innovation Just Had Its Best Week Ever, These Huge Winners
Last week, the S&P 500, Dow Jones and Nasdaq had their best gains of 2023. But the Ark Innovation ETF had its best week ever, up 18.6%.
Cathie Wood's Ark Innovation ETF (ARKK) has a history of consistently outperforming the broader market, regardless of whether the market is trending upward or downward. In the previous week, major indices like the S&P 500, Dow Jones, and Nasdaq (NDAQ) experienced their most significant gains of the year in 2023. However, the Ark Innovation ETF delivered its most remarkable performance ever, with an impressive increase of 18.6%.
This extraordinary performance can be attributed to substantial movements in some of its key holdings. For instance, Verve Therapeutics (VERV) saw a substantial weekly gain of 76% due to an expanded partnership with Eli Lilly (LLY). It's important to note that Verve Therapeutics represents a relatively small portion of the ARKK portfolio. Furthermore, Roku stock, now the top holding within ARKK, experienced a substantial surge of 50.4% in the past week, driven by strong earnings results from Roku (ROKU).
Other significant components within ARKK, such as Coinbase (COIN), Block (the parent company of Square) (SQ), DraftKings (DKNG), Crispr Therapeutics (CRSP), Shopify (SHOP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), Gingko Bioworks (DNA), and Palantir Technologies (PLTR), all posted impressive gains of more than 20%.
Much like Roku, these mentioned stocks experienced significant rallies driven by factors such as robust earnings reports, favorable news like FDA advancements or new partnerships, and positive developments within their competitive landscapes.
Notably, several of these stocks, including Roku, DraftKings, Shopify, and PLTR, generated strong buy signals in the past week, with Coinbase (COIN) stock being particularly close to a favorable entry point.
Tesla (TSLA), which has close ties to Cathie Wood and ARKK, had a successful week, recording a 6.1% increase in its value.
After Roku reported Q3 losses exceeding expectations on November 1st, the stock surged, driven by strong EBITDA, revenue, and new user metrics.
Coinbase offered cryptocurrency futures to eligible U.S. retail customers and reported Q3 performance, achieving nearly breakeven results and a 14% revenue increase.
Block (Square's parent company) reported Q3 earnings, providing bullish 2024 EBITDA guidance, resulting in a sharp stock price increase.
DraftKings posted Q3 losses below expectations but showed a 57% revenue increase and user growth.
Cathie Wood's gene-editing stocks, including Crispr Therapeutics, Verve Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Gingko Bioworks, saw significant gains.
Shopify beat earnings expectations, pushing its stock price higher.
Palantir Technologies reported Q3 earnings of 7 cents per share, an improvement over the previous year, and exceeded revenue expectations.
Cathie Wood made trades in her Ark Invest funds, including selling some DraftKings stock and increasing positions in gene-editing stocks.
Please note that stock prices and trading conditions mentioned are based on the provided data and may have changed since the information was reported.
$(ARKK)$ $(ARKF)$ $(ARKG)$ $(LLY)$ $(ROKU)$ $(COIN)$ $(SQ)$ $(PLTR)$ $(DKNG)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Cathie Wood's Ark Innovation ETF (ARKK) typically outpaces the overall market to the upside and downside. Last week, the S&P 500, Dow Jones and $Nasdaq(NDAQ)$ had their best gains of 2023. But the Ark Innovation ETF had its best week ever, up 18.6%.
Credit massive moves among key components. $Verve Therapeutics(VERV)$ (VERV), exploded for a 76% weekly gain on an expanded $Eli Lilly(LLY)$ (LLY) partnership. VERV stock is a relatively small ARKK hold. Roku stock, now the No. 1 holding in ARKK, vaulted 50.4% last week, thanks to robust Roku (ROKU) earnings results.
Coinbase (COIN), Square-parent $Block(SQ)$ (SQ), DraftKings (DKNG), Crispr Therapeutics (CRSP), $Shopify(SHOP)$ (SHOP), $Intellia Therapeutics(NTLA)$ (NTLA), Beam Therapeutics (BEAM), Gingko Bioworks (DNA) and Palantir Technologies (PLTR) all surged more than 20%.